Medicamen Organics makes a Blockbuster Debut, lists with 305% premium at  ₹137.85!Medicamen Organics makes a Blockbuster Debut, lists with 305% premium at  ₹137.85!

Medicamen Organics made a spectacular debut on the NSE SME, with its shares opening at ₹137.85, marking a 305.44% premium over the IPO price of ₹34. This strong opening underscores the significant investor enthusiasm for the stock.

Medicamen Organics IPO experienced overwhelming investor interest, being subscribed 993.56 times overall. Remarkably, retail investors subscribed 1,309.77 times, QIBs 173.03 times, and NIIs an astounding 1,343.83 times, demonstrating broad-based enthusiasm for the public offering.

Medicamen Organics Limited, with nearly three decades of experience, specialises in developing, manufacturing, and distributing pharmaceutical dosages. Operating two WHO GMP-approved facilities in Haridwar, they produce 84 products and are ISO 9001:2015 certified. They focus on exports, contract manufacturing, and providing affordable drugs while prioritising safety and quality under the leadership of Mr. Bal Kishan Gupta.

Medicamen Organics aims to use its IPO proceeds for international product registrations, upgrading plants, and expanding production, particularly Iron Tablets. Additionally, funds will support working capital and general corporate purposes such as strategic growth and marketing initiatives.